Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
editas medicine
gene editing
life sciences
national blog main
boston
crispr
crispr-cas9
katrine bosley
national top stories
san francisco blog main
san francisco top stories
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
andrew oxtoby
babies
base editing
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
broad institute
cas13
ceo
clinical hold
clinical study
clinical trials
combination
commissioner
congress
crispr therapeutics
cynthia collins
david liu
What
crispr
editas
3
×
medicine
3
×
cas
ceo
editing
gene
katrine
allergan
beam
big
bio
blessing
bosley
bosley's
bosley’s
bridge
bucks
check
clinical
crime
cusp
depart
departure
editor
exit
experimental
founders
gotten
guiding
harvard
humans
jump
mass
million
moves
partner
personnel
precise
regulatory
Language
Current search:
editas
×
medicine
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
